EL7.AI
GeopoliticsMedium•22 July 2026•
1 min read

Trump Imposes 100% Tariff on Imported Generic Drugs to Reshore Production

Key Facts

1President Trump announced a 100% tariff on imported generic drugs starting August 2028, rising to 200% a year later.
2The new policy aims to reshore pharmaceutical production to the US and protect critical supply chains.
3UBS warned that Indian pharma companies are highly exposed, providing 40% of US generic drug volume.

In a move reflecting an intensifying protectionist shift in U.S. trade policy, President Trump has announced a 100% tariff on imported generic drugs effective August 2028. The plan stipulates that these duties will escalate to 200% the following year, a strategy designed to compel manufacturers to reshore production to American soil. According to reports, the policy aims to secure critical supply chains and reduce national reliance on foreign pharmaceutical sources.

This policy shift places Indian pharmaceutical companies at significant risk, as UBS warned they are highly exposed due to providing 40% of the U.S. generic drug volume. Per market data, such a drastic increase in import costs could fundamentally restructure the global healthcare sector's competitive landscape, potentially severely impacting the profit margins and export revenues of international manufacturers reliant on the U.S. market.

Looking ahead at trade dynamics, investors are monitoring the upcoming U.S. Import Prices data scheduled for release on July 17, 2026, for early signals regarding imported goods inflation.